Turkish pharmaceutical sector’s R&D Spending surges 8.3-fold in five years
Research and development (R&D) spending in Türkiye’s pharmaceutical sector increased 8.3-fold between 2020 and 2024, rising from 676.2 million Turkish Liras to 5.6 billion liras.
According to data from the Pharmaceutical Sector Review Preliminary Report published by the Turkish Competition Authority, companies ranked among the world’s top 50 pharmaceutical firms by sales as of last year accounted for 88 percent of the U.S. pharmaceutical market and 49 percent of the Turkish market.
The figures indicate that globally active pharmaceutical companies hold a significant share of Turkey’s pharmaceutical market, while domestic and other international firms continue to maintain a strong position.
Globally, pharmaceutical R&D expenditure rose by 3 percent in 2025 compared with the previous year, reaching $201.3 billion. The United States ranked first in global pharmaceutical R&D spending with $130.1 billion.
